SCHEMBL20149817

SCHEMBL20149817

CC(C)C(=O)Nc1nc2c(ncn2[C@@H]2O[C@H](CO)[C@@H](N=[N+]=[N-])[C@H]2F)c(=O)[nH]1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.53
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
HPGD P15428 2/20 0.43
ALDH1A1 P00352 2/20 0.42
HIF1A Q16665 1/20 0.42
STING1 Q86WV6 1/20 0.39
ADORA3 P0DMS8 2/20 0.39
ADORA1 P30542 2/20 0.39
NOS1 P29475 1/20 0.39
POLA1 P09884 1/20 0.37
PDE2A O00408 1/20 0.37
ADORA2A P29274 1/20 0.37
ADRA1A P35348 1/20 0.37
PDE4D Q08499 1/20 0.37
PDE3A Q14432 1/20 0.37
NT5E P21589 1/20 0.37
IMPDH2 P12268 3/20 0.36
IMPDH1 P20839 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20154789 1.00 KDM4E (0.53) KDM4ETAS1R3TAS1R1HPGDALDH1A1
SCHEMBL20149813 0.94 KDM4E (0.53) KDM4ETAS1R3TAS1R1HPGDALDH1A1
SCHEMBL20154880 0.94 KDM4E (0.53) KDM4ETAS1R3TAS1R1HPGDALDH1A1
SCHEMBL23630081 0.91 KDM4E (0.54) KDM4ETAS1R3TAS1R1HPGDALDH1A1
SCHEMBL23630085 0.91 KDM4E (0.54) KDM4ETAS1R3TAS1R1HPGDALDH1A1
SCHEMBL18954932 0.90 ALDH1A1 (0.55) KDM4ETAS1R3TAS1R1HPGDALDH1A1
SCHEMBL25496780 0.90 KDM4E (0.54) KDM4ETAS1R3TAS1R1HPGDALDH1A1
SCHEMBL18954935 0.90 ALDH1A1 (0.55) KDM4ETAS1R3TAS1R1HPGDALDH1A1
SCHEMBL19503072 0.90 ALDH1A1 (0.55) KDM4ETAS1R3TAS1R1HPGDALDH1A1
SCHEMBL23169669 0.88 TAS1R3 (0.46) KDM4ETAS1R3TAS1R1ALDH1A1STING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180135054-A1 MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE ALIOS BIOPHARMA, INC. (US) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180135054-A1 MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE NSUN2, ADAR, POLM KDM4E 2928/4885TAS1R3 4579/4885TAS1R1 4780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.